File Entry: Chemotherapeutic Agents-Method Development and Pharmacological study

Created: 2017-08-28 06:27:08
Information Version 1 (of 1)

Version created on: 2017-08-28 06:27:08

Information Description

Dr Krishnasarmapathy. EDITORAL BOARD MEMBER-Hospital and Clinical Pharmacy
1Pharmacological studies of anti-cancer drugs
Cancer is a worldwide problem. Finding novel
compositions and methods for treating cancer is of
interest. The treatment of cancer falls into three
general categories: chemotherapy, radiation therapy
and surgery. Often, therapies are combined since a
combination of therapies increases the probability the
cancer will be eradicated as compared to treatment
strategies utilizing a single therapy. Typically, the
surgical excision of large tumor masses is followed
by chemotherapy and/or radiation therapy.
Chemotherapeutic agents can work in a number of
ways. For example, chemotherapeutics can work by
interfering with cell cycle progression or by
generating DNA strand breaks. If the cancer cell is
not able to overcome the cell cycle blockage or cell
injury caused by the therapeutic compound, the cell
will often die via apoptotic mechanisms. The use of a
single chemotherapeutic agent in the treatment of
cancer, with or without surgery or radiation, has
several disadvantages. Commonly, cancer cells
develop resistance to the chemotherapeutic agent.
Such resistance results either in the requirement for
higher dosages of the drug and/or the renewed
spread of the cancer. Chemotherapeutic agents can
be toxic to the patient. Therefore, there is a practical
upper limit to the amount that a patient can receive.
However, if a second agent can be developed to
inhibit the pathway causing resistance, cancer cells
may become susceptible to the effects of the
chemotherapeutic agent. The design of a drug to
overcome resistance to the chemotherapeutic
treatment of cancer should be approached with the
goals of 1) finding a combination that reverses
resistance and not merely improves the activity of the
chemotherapeutic with respect to activity on the
tumor, and 2) finding a second drug that does not
potentiate the toxic effects of the first
chemotherapeutic agent. These conditions require a
great deal of empirical testing of agents known to
have anticancer properties with agents that either
may have anticancer properties, or that may augment
the first agent in other ways. Unfortunately, such
approaches have thus far proven largely
unsuccessful for combinations of many anticancer
agents. Therefore, there exist insufficient therapies
that reverse resistance to chemotherapy for the
treatment of cancer

Information Download

Information License

All versions of this File are licensed under:

Information Credits (1)


Information Attributions (0)



Information Tags (0)


Log in to add Tags

Information Shared with Groups (0)


Information Featured In Packs (0)


Log in to add to one of your Packs

Information Attributed By (0)



Information Favourited By (0)

No one

Information Statistics

107 viewings


[ see breakdown ]


Version History

In chronological order:

Comments Comments (0)

No comments yet

Log in to make a comment

What is this?

Linked Data

Non-Information Resource URI:

Alternative Formats